Several drug pricing experts say without key details, it’s hard to call the individual pharma deals a win for the Trump administration.
Merith Basey, executive director of Patients for Affordable Drugs Now, said in response to the updated CBO analysis that “the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback